A study published this week by researchers at the University of Hong Kong’s Faculty of Medicine said that the omicron variant replicates 70 times faster in human airways than delta, but infection in the lungs appears to be less severe compared with the original virus strain.
I call BS! 70X is mass cell destruction! Should be worse a whole lot quicker! Well at least in the countries that don't use Ivermectin.
https://www.cnbc.com/2021/12/17/no-evidence-that-covid-omicron-variant-less-severe-than-delta-uk-study.html
I call BS! 70X is mass cell destruction! Should be worse a whole lot quicker! Well at least in the countries that don't use Ivermectin.
https://www.cnbc.com/2021/12/17/no-evidence-that-covid-omicron-variant-less-severe-than-delta-uk-study.html
Recent MRK News
- Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke • Business Wire • 04/28/2026 10:45:00 AM
- Futures Suggest Flat Start for Wall Street: Dow Jones, S&P, Nasdaq • IH Market News • 04/27/2026 01:13:41 PM
- Futures Indicate Muted Start for Wall Street: Dow Jones, S&P, Nasdaq • UK Market News • 04/27/2026 01:13:31 PM
- Organon Jumps 15% as Sun Pharma Agrees $11.8bn Buyout • IH Market News • 04/27/2026 10:11:06 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 04/24/2026 11:30:33 AM
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc. • Business Wire • 04/24/2026 10:45:00 AM
- Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation • PR Newswire (US) • 04/22/2026 12:00:00 PM
- FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir) • Business Wire • 04/21/2026 06:11:00 PM
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) • Business Wire • 04/21/2026 10:45:00 AM
- FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer • Business Wire • 04/20/2026 10:48:00 AM
- European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season • Business Wire • 04/17/2026 11:49:00 AM
- New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada • PR Newswire (Canada) • 04/15/2026 11:00:00 AM
- Un nouveau sondage révèle que la sensibilisation au VPH ne suit pas le rythme de certaines tendances en matière de cancers liés au VPH au Canada • PR Newswire (Canada) • 04/15/2026 11:00:00 AM
- Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy • Business Wire • 04/13/2026 11:00:00 AM
- Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy • Business Wire • 04/13/2026 11:00:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/08/2026 08:32:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/08/2026 08:28:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/08/2026 08:25:08 PM
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc. • Business Wire • 04/07/2026 01:00:00 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 04/07/2026 11:00:59 AM
- Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration • Business Wire • 04/02/2026 10:50:00 AM
- European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens • Business Wire • 04/02/2026 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:47:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:44:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 05:42:51 PM

